EcoDrugPlus

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSGACG00000004869
Gene Symbol: MTOR
1 Cross references
222 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSGACG00000015952
Gene Symbol: MC1R
2 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSGACG00000005570
Gene Symbol: MC4R
2 Cross references
211 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSGACG00000016880
Gene Symbol: MTNR1AA
1 Cross references
190 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSGACG00000010305
Gene Symbol: MME
2 Cross references
236 Possible Orthologues:

Methionyl Aminopeptidase 2b

Ensembl ID : ENSGACG00000020059
Gene Symbol: METAP2B
2 Cross references
229 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSGACG00000014421
Gene Symbol: MAPK1
1 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSGACG00000016396
Gene Symbol: MAPK10
1 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSGACG00000019107
Gene Symbol: MAPK11
1 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSGACG00000007676
Gene Symbol: MAPK14
2 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSGACG00000013102
Gene Symbol: MAPK3
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSGACG00000007039
Gene Symbol: MAPK8A
2 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).